UPDATE: Dougherty Downgrades Hologic; Lowers PT
According to a research report published this morning, Dougherty has downgraded Hologic (NASDAQ: HOLX) to Neutral, and lowered PT from $26 to $20.
In the report, Dougherty commented, "Hologic reported F2Q:12 sales of $471.2MM (vs. our $473.0MM; Street $474.0MM) and EPS of $0.33 (vs. our $0.34; Street $0.33)—we note that the Breast Health business was surprisingly weaker than expected at $218.6MM (vs. our $225.4MM; Street $222.0MM). We would have expected a healthier Breast Health business, given the Dimensions Tomosynthesis Year-2 rollout. Ultimately, we ponder whether the Gen-Probe transaction is a smoke-screen for a weaker base business."
Hologic closed yesterday at $19.11.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.